Objective: It is now recognized that mean circulating dehydroepiandrosterone sulfate (DHEAS) concentrations in most midlife women exhibit a positive inflection starting in early perimenopause, continuing through early postmenopause and returning to early perimenopausal levels by late postmenopause. This rise in mean DHEAS is accompanied by concomitant rises in testosterone (T), dehydroepiandrosteone (DHEA), and androstenedione (Adione) and an equal rise in androstenediol (Adiol). These observations suggest that there is a specific relationship between the circulating levels of steroids emanating from the adrenal glands, declining ovarian function, and the stages of the menopausal transition. This study was designed to test the hypothesis that the menopausal stageY specific change in circulating DHEAS is associated with concomitant changes in the circulating pattern of adrenal steroids and that some of these adrenal androgens could influence the circulating estrogen/androgen balance.
T he decline in circulating dehydroepiandrostenedione sulfate (DHEAS), evident from early adulthood in both men and women in cross-sectional and longitudinal studies, has been interpreted as an indicator of somatic aging independent of gonadal function and is used clinically in that capacity. The classic and expected profile of mean DHEAS is a continuous gradual decline with advancing age. However, we have reported that, in contrast to the prevailing dogma, 1<6 serum concentrations of adrenal androgens in midlife women do not always demonstrate a continuous, age-related decrease but variably exhibit a transient increase in the late perimenopause. 7<9 At the present time, the underlying mechanism responsible for this increase in a circulating adrenal steroid and its relationship to the decline in ovarian function during the menopausal transition (MT) remains to be elucidated. Understanding this phenomenon may be important because of its potential as an endocrine contributor to the variability in perimenopausal symptoms, differences in circulating steroid hormone concentrations, and/or control of adrenal function. The present study was designed to test the hypothesis that early to late perimenopausal change in mean circulating DHEAS is closely associated with similar changes in other circulating adrenal androgens.
METHODS
This study reports results from serum samples selected from the overall Study of Women's Health Across the Nation (SWAN) population that has been previously reported. 10 Briefly, SWAN is a multisite longitudinal cohort study being conducted in community-based groups of women who belonged to one of five ethnic/racial groups. Eligibility criteria for the SWAN longitudinal cohort were age of 42 to 52 years, intact uterus and at least one ovary, no current use of estrogens or other medications known to affect ovarian function, at least one menstrual period in the 3 months before screening, and self-identification in one of five eligible ethnic groups. Institutional review board approval was obtained at each study site.
A total of 120 stored serum samples were first selected to represent four longitudinal DHEAS profiles of individual women to assess annual changes in mean adrenal steroid hormones ( Fig. 1 ). Annual profile 1 (n = 30), the profile used as reference, includes data from women who exhibited the classic and expected mean DHEAS concentration at baseline followed by a subsequent gradual decline over the next 2 years (Table 1 ). In profiles 2, 3, and 4 (n = 30 each), the selected data were from women who had an initial transitory fall and then rise in circulating mean DHEAS initially from their SWAN baseline assessment. 11 Profile 2 is unique in that it has a mean DHEAS baseline that is more than 1 SD below the overall population mean and has a DHEAS change profile characterized by a DHEAS fall from year 0 to year 1, with a rise in the subsequent year. Profile 3 is unique in that it has a mean baseline that is within 1 SD of the overall mean and is followed by a mean DHEAS decline the next year and followed by a rise in year 2. Profile 4 has a mean DHEAS baseline that is greater than 1 SD above the population mean and has a DHEAS change profile whereby mean DHEAS falls from year 0 to year 1 followed by a rise in year 2. Therefore, profiles 2, 3, and 4 all have profiles that represent a fall followed by a rise in mean DHEAS concentration, but all profiles link the subsequent change to a different baseline (year 0) DHEAS mean concentration ( Fig. 1 ).
Only white (59%) and African American (41%) women were included in the study. However, because circulating DHEAS concentrations at baseline are ethnically distributed, the proportion of each ethnicity was not equal in the four profiles. The percentage of African Americans was greatest in profile 2 (55%) and lowest in profile 4 (22%).
DHEAS assay
The DHEAS assay is a competitive immunoassay run on Bayer Diagnostic's ACS-180 automated analyzer using chemiluminescent technology. This assay was developed de novo ; of reference DHEAS with a subsequent increase; n = 30), 3 (at the x ; of reference DHEAS; n = 30), and 4 (91 SD above the x ; of the reference DHEAS with an immediate decline and recovery; n = 30) illustrate the samples in which there was the transitory fall and then rise, a profile that has been uniquely reported in SWAN enrollees. Boxes represent the SEM and bars the range. DHEAS, dehydroepiandrosterone sulfate. for SWAN and uses rabbit polyclonal anti-DHEAS antibody, goat antirabbit immunoglobulin G (IgG) labeled with superparamagnetic particles (PMP), and DHEAS labeled with dimethylacridinium ester (DMAE). Ten microliters of serum is required for the assay in addition to the sufficient dead volume for aspiration and repeat. The assay range is 0.04 to 26.1 KM (1.52-1,020 Kg/dL) and is standardized against DHEAS obtained from Steraloids (Newport, RI). The interassay and intra-assay coefficients of variation were 13% and 10%, respectively.
Cortisol assay
The cortisol assay is a competitive immunoassay run on Bayer Diagnostic's ACS-180 automated analyzer using chemiluminescence technology. The assay uses cortisol labeled with DMAE, a polyclonal rabbit anticortisol antibody, and a monoclonal mouse antirabbit antibody coupled with PMP. The interassay and intra-assay coefficients of variation were 4.8% and 3.6%, respectively.
Testosterone assay
The testosterone (T) assay is a competitive immunoassay modified to run on Bayer Diagnostic's ACS-180 automated analyzer using chemiluminescence technology. 12 The assay uses T labeled with DMAE, a polyclonal rabbit anti-T antibody, and a monoclonal mouse antirabbit antibody coupled with PMP. Forty-five microliters of serum is required for the assay, in addition to sufficient dead volume for aspiration and repeat assay determinations. The SWAN reporting range for the T assay is 0.4 to 3.5 nM (10-100 ng/dL). The actual assay range is 0.07 to 16.6 nM (2-478 ng/dL). The ACS T assay is standardized analytically and confirmed by gas chromatographymass spectrometry. The interassay and intra-assay coefficients of variation were 12% and 7%, respectively.
Androstenedione and androstenediol assays
Androstenedione (Adione) and 5-androstene-3A,17A-diol (Adiol) were analyzed in a single aliquot (0.8 mL) of serum using radioimmunoassay (RIA) methods. 13, 14 The analytes were extracted from plasma using hexane/ethyl acetate (3:2) and, after evaporation of the organic solvents, the extract was redisolved in isooctane and applied to a celite partition column impregnated with ethylene glycol. Adione and Adiol were eluted with isooctane and 40% toluene in isooctane, respectively. After evaporation of the eluates, each residue was reconstituted in assay buffer, and appropriate aliquots were taken for RIA. Each RIA uses a highly specific antiserum in conjunction with an iodinated (Adione) or tritiated (Adiol) radioligand. After an appropriate incubation period, antibodybound versus unbound hormones were separated using either a second antibody (Adione) or dextran-coated charcoal (Adiol). The antibody-bound hormone was then counted after centrifugation. Interassay and intra-assay coefficients of variation were 8% and 10% at 460 and 1450 pg/mL, respectively, for Adione and 13% and 11% at 460 and 1210 pg/mL, respectively, for Adiol.
Sex hormone-binding globulin assay
The sex hormoneYbinding globulin (SHBG) assay is a competitive immunoassay run on Bayer Diagnostic's ACS-180 automated analyzer using chemiluminescent technology. 10 The assay was developed de novo and uses a rabbit polyclonal anti-SHBG antibody, SHBG labeled with DMAE, and goat antirabbit IgG coupled with PMP. Forty microliters of serum is required for the assay in addition to sufficient dead volume for aspiration and repeat. The expected values are from 20 to 130 nM. The reporting range for the SHBG assay is 10 to 150 nM (actual assay range, 1.95-250 nM). The assay is standardized against SHBG obtained from Wein Laboratories Inc. (Concord, MA) . The interassay and intra-assay coefficients of variation were 12% and 9%, respectively.
Estradiol assay
The offline estradiol (E 2 ) assay 15 is a semiautomated competitive immunoassay with manual steps and an offline incubation. Standards, quality control preparations, and serum samples are pipetted into 12 Â 75 polypropylene tubes by hand with a dilution of antibody reagent and then incubated. First, DMAE-labeled E 2 and rabbit anti-E 2 antibodies are added to the tubes and incubated. Afterward, all tubes are placed on Bayer Diagnostic's ACS-180 automated analyzer with monoclonal mouse antirabbit IgG coupled to PMP for analysis. One millilter of serum is required for the assay in addition to sufficient dead volume for aspiration and repeats. The SWAN reporting range for the E 2 assay is 3.7 to 734 pM (1-200 pg/mL). The ACS E2-6 Master Curve standards are manufactured and evaluated by gas chromatography-mass spectrometry. The interassay and intra-assay coefficients of variation were 14% and 9%, respectively.
Data analysis
One-way analysis of variance was used to test whether the values of steroids (androgens, E 2 ) as well as SHBG in the reference DHEAS profile (profile 1) were different from those in the DHEAS profile with unique DHEAS increase patterns (profiles 2-4). Correlation analysis was further applied to test the strength and the direction of associations of circulating Adione, Adiol, and T with DHEAS at the levels of baseline. Hormone values were log transformed before analysis. A P value less than 0.05 was considered to be statistically significant. Data analysis was done using StatView Version 5.0.1.0 (1998, SAS Institute, Inc.) and SAS version 8.0. Simple linear regression was used to illustrate the relationships between T, DHEAS, Adione, and Adiol. In the regression analyses, all hormone concentrations were log transformed before analysis and then back transformed to remove skewness.
RESULTS
Although there was no statistically significant difference in comparing the age of the reference profile 1 women with the characteristics of the other three profiles, there was a nonsignificant trend that the reference women had a greater body mass index and were more likely to be perimenopausal than premenopausal ( Table 1 ). Women in the reference profile 1 were more likely to report having hot flashes in the 2 weeks before the baseline examination compared with the other profiles.
The four distinct hormone profiles contrast an expected continuing gradual decline in mean DHEAS as shown in profile 1 (Fig. 1, Table 2 ) to the main patterns of increase and decline that were captured in the larger SWAN study. These .26 The reference profile shows a DHEAS fall in subsequent years, whereas profiles 2 to 4 show a fall in the subsequent year and then rise. P values are provided to illustrate the significance between the mean (profile 3) and G1 SD below the mean (profile 2) and between the mean (profile 3) and 91 SD above the mean (profile 4). DHEAS, dehydroepiandrosterone sulfate; SHBG, sex hormoneYbinding globulin; E 2 , estradiol.
FIG. 2. Linear regressions of the four hormones described in this study (Log e DHEAS and Log e T versus Log e Adiol and Adione). A, B:
show Log e DHEAS versus Ln Adiol (n = 119, P G 0.0001) and Ln Adione (n = 119, P G 0.0001), respectively. C, D: show Ln T vs Ln Adiol (n = 117, P G 0.0001) and Ln Adione (N = 117, P G 0.0001), respectively. Some samples were excluded for lack of T, Adiol, or Adione assay results. DHEAS, dehydroepiandrosterone sulfate; T, testosterone; Adiol, androstenediol; Adione, androstenedione. patterns most likely represent the same basic physiologic mechanism but appear as different patterns because the women were recruited at different times relative to an inflection in DHEAS production.
Baseline mean DHEAS values were associated with different androgen profiles using regression analysis. DHEAS decline and increase were attended by concomitant changes in Adiol and, to a lesser degree, T and Adione (Fig. 2) . Furthermore, a consistently stronger correlation was found between DHEAS and Adiol (0.71, P G 0.05), irrespective of the baseline level of DHEAS compared with T (0.20, P G 0.05) and Adione (0.28, P G 0.05). Circulating mean cortisol concentrations were not correlated with DHEAS and there was no difference in mean cortisol concentrations among the different profiles (data not shown).
DISCUSSION
A menopausal stage-specific rise in mean serum DHEAS is observed in most women between the early perimenopause and early postmenopause stages of the MT 8 ; it also occurs after bilateral salpingo-oophorectomy during the early perimenopause. 9 This change in DHEAS is accompanied by simultaneous and similar changes in circulating adrenal androgens but not cortisol. Biologically, an increase in these androgenic steroids could be important for women approaching menopause given that DHEAS, resulting in a rise in DHEA, provides a reservoir of substrate for peripheral conversion into other bioactive steroids. Interestingly, one of these metabolites, Adiol, has both inherent estrogenic and androgenic activity 16, 17 and possibly contributes directly to the circulating estrogen pool and alterations in the circulating estrogen to androgen ratio. 18 This previous report showed the relationship between the four adrenal androgens (DHEAS, T, Adiol, and Adione 18 ) and we speculate that these hormones would move together; the present data show that increasing circulating levels of DHEAS are accompanied by concomitant increases in Adiol, Adione, and T in perimenopausal women. This is consistent with the literature, which indicates that circulating DHEAS is a reliable index of total androgens in women. 19 Circulating Adiol concentrations were more robustly correlated to DHEAS during all segments of the perimenopausal dynamics of DHEAS as compared with Adione and T in the longitudinal analysis presented here. This observation of a strong positive correlation between DHEAS and Adiol is consistent with the concept that Adiol is a peripheral conversion product of DHEA. It is also possible that it is a direct secretory product of the adrenal glands. The lack of correlation between DHEAS and E 2 , however, does not support the contention that peripheral metabolism of DHEA contributes significantly to circulating E 2 . The absence of data demonstrating the conversion of exogenous DHEA to Adiol concentrations similar to those observed in this study also suggests that much or most of the circulating Adiol that occurs during the MT is a result of direct secretion by the adrenal glands. Although Adiol is a weak estrogen agonist compared with E 2 , the serum concentrations of Adiol in midlife women are substantially higher than levels of E 2 during the MT in most women. 18 The fivefold or greater range of circulating Adiol levels, from 689 pM (200 pg/mL) to greater than 3.8 nM (1,100 pg/mL), presents the possibility that some women may experience estrogen action from a sufficient increase in Adiol. In contrast, the range of circulating E 2 concentrations is only threefold (20-60 pg/mL) when measured during the early follicular phase of the menstrual cycle. Therefore, during the MT, the between-woman difference in circulating Adiol concentrations exceeds the between-woman difference in E 2 by up to 1,000-fold, potentially providing a more variable source of estrogenic, albeit weak, support.
Recent interest has arisen in identifying the direct effects of steroid hormone metabolites that may activate steroid hormone receptors. 17 The present data provide additional and direct evidence for a potential role of steroids emanating from the adrenal glands in modulating the symptoms and health outcomes of midlife women. The circulating levels for Adione and T increased only twofold and threefold, respectively, and only a modest statistically significant difference was found in the mean Adione concentrations across the total range of DHEAS concentrations. This modest increase in Adione and T in association with the robust rise in DHEA supports the concept that although there is probably an increased conversion of DHEA to Adione and T in women during early-tolate MT, the much greater rise in DHEA suggests that changes in adrenal secretion rates rather than just peripheral conversion may be important in the support of sex steroidYsensitive tissues. To be clear, this report does not demonstrate that a direct secretion of steroids by the adrenal gland is responsible, but in the face of no evidence in the literature to suggest that changes in metabolism or clearance rates could account for such concentration changes, we interpret the observed increase as caused by increased production rate. Therefore, increased Adiol production (with inherent estrogenic activity), rather than an elevation of DHEA as a prohormone, suggests an alternative explanation for the positive physiological effects that have previously been attributed primarily to endogenous DHEA.
The grouping of women based on initial circulating DHEAS concentrations created trajectory groups that were ethnically divergent. This is to be expected because previous reports have demonstrated ethnic differences in DHEAS in middle-aged women, 8, 20 in which whites have higher, and African Americans lower, baseline DHEAS. Despite this apparent initial ethnicity-based difference in baseline DHEAS, the relative change in the complement of adrenal androgens during the MT was similar for all four trajectories. Therefore, the absolute peak concentrations of adrenal androgens remain ethnically distinct.
This study failed to detect a clear pattern in circulating cortisol with respect to DHEAS profiles, which is consistent with a separate and selective acceleration of the $5-C19 androgen synthetic pathway and argues against a Bspill-over[ resulting from an increased adrenocorticotropin drive. Increased adrenocorticotropin drive would have selective preference for the $4 pathway, resulting in increases in Adione and T concentrations, which is opposite to that observed in the present study. The present data also argue that the observed increase in adrenal secretory activity is not a result of a stress response, either specific to the perimenopause or independent of it. Although cortisol was measured in these profiles, these results should be interpreted with caution because samples for the SWAN cohort were only collected between 6 and 10 AM.
CONCLUSIONS
The data presented herein illustrate that there are wider between-woman differences in circulating adrenal steroids during the MT and immediately after menopause than was previously appreciated. Because approximately 85% of all women have some rise in DHEAS during the MT, 8 we expect that the increased contribution of adrenal steroids as demonstrated here is a common event for most women. Although circulating E 2 concentrations are known to decline in women during the course of the MT, 12 the current data demonstrate that a modest decline in circulating levels of E 2 in late perimenopause is associated with a much broader range of circulating levels of Adiol and DHEA. Therefore, the change in steroids emanating from the adrenal glands during the MT may be an important contributor to the overall change in sex steroid hormone balance during the MT, and it may be a better indicator of phenotype than the smaller decline in ovarian steroid production. These observations raise the question as to the possibility that differences in adrenal steroid levels may predict difference in symptoms and health outcomes. However, because the rise in adrenal steroids was recognized only when a large number of longitudinal samples were evaluated, 8 it is improbable that parallel changes in symptoms or health outcomes would be detected in this relatively small cross-sectional investigation. Future longitudinal studies are planned that will address these interesting possibilities.
